Sign In
Buy ALNY
Alnylam Pharmaceuticals Earnings Calls
| Release date | Oct 30, 2025 |
| EPS estimate | $0.561 |
| EPS actual | $2.90 |
| EPS Surprise | 416.93% |
| Revenue estimate | 959.401M |
| Revenue actual | 1.249B |
| Revenue Surprise | 30.19% |
| Release date | Jul 31, 2025 |
| EPS estimate | -$0.544 |
| EPS actual | $0.320 |
| EPS Surprise | 158.85% |
| Revenue estimate | 662.872M |
| Revenue actual | 773.689M |
| Revenue Surprise | 16.72% |
| Release date | May 01, 2025 |
| EPS estimate | -$0.89 |
| EPS actual | -$0.0100 |
| EPS Surprise | 98.88% |
| Revenue estimate | 585.142M |
| Revenue actual | 594.189M |
| Revenue Surprise | 1.55% |
| Release date | Feb 13, 2025 |
| EPS estimate | -$0.620 |
| EPS actual | $0.0600 |
| EPS Surprise | 109.68% |
| Revenue estimate | 582.606M |
| Revenue actual | 593.166M |
| Revenue Surprise | 1.81% |
Last 4 Quarters for Alnylam Pharmaceuticals
Below you can see how ALNY performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Feb 13, 2025 |
| Price on release | $264.89 |
| EPS estimate | -$0.620 |
| EPS actual | $0.0600 |
| EPS surprise | 109.68% |
| Date | Price |
|---|---|
| Feb 07, 2025 | $276.19 |
| Feb 10, 2025 | $274.06 |
| Feb 11, 2025 | $268.99 |
| Feb 12, 2025 | $265.96 |
| Feb 13, 2025 | $264.89 |
| Feb 14, 2025 | $256.45 |
| Feb 18, 2025 | $250.00 |
| Feb 19, 2025 | $250.51 |
| Feb 20, 2025 | $251.00 |
| 4 days before | -4.09% |
| 4 days after | -5.24% |
| On release day | -3.19% |
| Change in period | -9.12% |
| Release date | May 01, 2025 |
| Price on release | $255.13 |
| EPS estimate | -$0.89 |
| EPS actual | -$0.0100 |
| EPS surprise | 98.88% |
| Date | Price |
|---|---|
| Apr 25, 2025 | $251.56 |
| Apr 28, 2025 | $254.85 |
| Apr 29, 2025 | $257.19 |
| Apr 30, 2025 | $263.24 |
| May 01, 2025 | $255.13 |
| May 02, 2025 | $259.39 |
| May 05, 2025 | $273.55 |
| May 06, 2025 | $269.81 |
| May 07, 2025 | $276.55 |
| 4 days before | 1.42% |
| 4 days after | 8.40% |
| On release day | 1.67% |
| Change in period | 9.93% |
| Release date | Jul 31, 2025 |
| Price on release | $392.24 |
| EPS estimate | -$0.544 |
| EPS actual | $0.320 |
| EPS surprise | 158.85% |
| Date | Price |
|---|---|
| Jul 25, 2025 | $328.81 |
| Jul 28, 2025 | $324.79 |
| Jul 29, 2025 | $330.55 |
| Jul 30, 2025 | $339.80 |
| Jul 31, 2025 | $392.24 |
| Aug 01, 2025 | $401.80 |
| Aug 04, 2025 | $419.56 |
| Aug 05, 2025 | $418.91 |
| Aug 06, 2025 | $428.14 |
| 4 days before | 19.29% |
| 4 days after | 9.15% |
| On release day | 2.44% |
| Change in period | 30.21% |
| Release date | Oct 30, 2025 |
| Price on release | $449.56 |
| EPS estimate | $0.561 |
| EPS actual | $2.90 |
| EPS surprise | 416.93% |
| Date | Price |
|---|---|
| Oct 24, 2025 | $463.43 |
| Oct 27, 2025 | $478.58 |
| Oct 28, 2025 | $475.91 |
| Oct 29, 2025 | $481.59 |
| Oct 30, 2025 | $449.56 |
| Oct 31, 2025 | $456.04 |
| Nov 03, 2025 | $433.92 |
| Nov 04, 2025 | $423.47 |
| Nov 05, 2025 | $434.56 |
| 4 days before | -2.99% |
| 4 days after | -3.34% |
| On release day | 1.44% |
| Change in period | -6.23% |
Alnylam Pharmaceuticals Earnings Call Transcript Summary of Q3 2025
Alnylam reported strong Q3 2025 results driven by the AMVUTTRA ATTR‑CM U.S. launch and continued strength in its TTR franchise. Key financials: total net product revenues of $851M (+103% YoY), TTR franchise revenues of $724M (+135% YoY), and collaboration revenue of $352M driven in part by a $300M Roche milestone tied to the ZENITH trial start. Management raised full‑year 2025 net product revenue guidance to $2.95B–$3.05B (previously $2.65B–$2.8B), reflecting confidence in the AMVUTTRA launch; TTR franchise guidance was raised to $2.475B–$2.525B. Commercial update: U.S. AMVUTTRA ATTR‑CM patient demand roughly doubled QoQ in Q3, with broad access, near‑complete health‑system setup, strong first‑line adoption and low out‑of‑pocket costs for most patients. Ex‑U.S. launches (notably Japan and Germany) will contribute more meaningfully in 2026 as pricing and reimbursement complete. R&D/pipeline: two Phase III trials initiated or imminent — ZENITH (zilebesiran cardiovascular outcomes, ~11,000 patients) and TRITON‑PN (nucresiran in hATTR‑PN, ~125 patients) — and ALN‑6400 (plasminogen) moved into Phase II in HHT; a Phase I for MAPT (ALN‑5288) in Alzheimer’s launched. Gross margin pressures expected from higher AMVUTTRA royalties; non‑GAAP operating expenses guided to $2.15B–$2.2B. Company also completed refinancing activity (new convertible notes, repurchase of 2027 notes) and added a $500M revolver.
